Savvy Updates, 1/3/22: Beta Bionics Pivotal Trial, Log4j Cybersecurity, Exercise at High Altitudes, Cannabis and DKA, Amazon Pharmacy Shake-up, Endo Fellowships

Beta Bionics Announces Data Lock of the Insulin-Only Bionic Pancreas Pivotal Trial and Enrollment into the Screening Protocol of the Bihormonal Bionic Pancreas Pivotal Trial was released by Beta Bionics on GlobeNewswire.com, 22 December 2021.  

Beta Bionics, Inc., a clinical stage medical technology company committed to the design, development, and commercialization of the iLet® Bionic Pancreas System, today announced the completion of the randomized controlled trial for the Insulin-Only Bionic Pancreas Pivotal Trial and enrollment into the screening protocol of the Bihormonal Bionic Pancreas Pivotal Trial at Massachusetts General Hospital. Data lock for the randomized controlled trial occurred last week.

Leave a Reply

Your email address will not be published.